Daewon Pharmaceutical Co (XKRX:003220) Beneish M-Score: -2.79 (As of Aug. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XKRX:003220 Daewon Pharmaceutical Co Ltd XKRX:003220
72 GF Score
Price ₩7,960.00
GF Value ₩14,490.07
Valuation Significantly Undervalued
! 9 Warning Signs
View Full Analysis

What is Daewon Pharmaceutical Co Beneish M-Score?

Daewon Pharmaceutical Co XKRX:003220 -0.25% 72 Beneish M-Score is -2.79 as of Aug. 15, 2026. GuruFocus rates XKRX:003220 with a GF Score™ of 72/100 and a GF Value™ of ₩14,490.07 (Significantly Undervalued). The stock has 9 warning signs investors should review. Among 913 Drug Manufacturers companies, Daewon Pharmaceutical Co ranks better than 74.37% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.79 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Daewon Pharmaceutical Co's Beneish M-Score or its related term are showing as below:

XKRX:003220' s Beneish M-Score Range Over the Past 10 Years
Min: -3.01   Med: -2.52   Max: -2.04
Current: -2.79

During the past 13 years, the highest Beneish M-Score of Daewon Pharmaceutical Co was -2.04. The lowest was -3.01. And the median was -2.52.


Daewon Pharmaceutical Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Daewon Pharmaceutical Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Daewon Pharmaceutical Co Beneish M-Score Chart

Daewon Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.52 -2.18 -2.48 -2.67 -2.75

Daewon Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.01 -2.87 -2.75 -2.74 -2.79

XKRX:003220 vs ZTS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Daewon Pharmaceutical Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Daewon Pharmaceutical Co Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daewon Pharmaceutical Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Daewon Pharmaceutical Co's Beneish M-Score falls into.


XKRX:003220
72GF Score
Daewon Pharmaceutical Co Ltd XKRX:003220
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Daewon Pharmaceutical Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Daewon Pharmaceutical Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.801+0.528 * 1.02+0.404 * 1.0186+0.892 * 1.0183+0.115 * 0.9087
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1042+4.679 * -0.027122-0.327 * 1.0271
=-2.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun26) TTM:Last Year (Jun25) TTM:
Total Receivables was ₩57,999 Mil.
Revenue was 152831.677 + 158057.595 + 159806.912 + 143940.264 = ₩614,636 Mil.
Gross Profit was 70865.884 + 75082.887 + 73565.187 + 61107.006 = ₩280,621 Mil.
Total Current Assets was ₩233,559 Mil.
Total Assets was ₩573,328 Mil.
Property, Plant and Equipment(Net PPE) was ₩220,524 Mil.
Depreciation, Depletion and Amortization(DDA) was ₩24,592 Mil.
Selling, General, & Admin. Expense(SGA) was ₩136,705 Mil.
Total Current Liabilities was ₩207,869 Mil.
Long-Term Debt & Capital Lease Obligation was ₩62,045 Mil.
Net Income was 4027.794 + 2422.091 + 13596.905 + -17414.757 = ₩2,632 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ₩0 Mil.
Cash Flow from Operations was -4386.008 + 9209.998 + 30612.99 + -17255.134 = ₩18,182 Mil.
Total Receivables was ₩71,110 Mil.
Revenue was 143855.801 + 157831.742 + 145070.409 + 156831.296 = ₩603,589 Mil.
Gross Profit was 63388.51 + 74727.047 + 67779.685 + 75181.342 = ₩281,077 Mil.
Total Current Assets was ₩247,276 Mil.
Total Assets was ₩581,370 Mil.
Property, Plant and Equipment(Net PPE) was ₩215,389 Mil.
Depreciation, Depletion and Amortization(DDA) was ₩21,605 Mil.
Selling, General, & Admin. Expense(SGA) was ₩121,577 Mil.
Total Current Liabilities was ₩205,765 Mil.
Long-Term Debt & Capital Lease Obligation was ₩60,719 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(57998.796 / 614636.448) / (71110.148 / 603589.248)
=0.094363 / 0.117812
=0.801

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(281076.584 / 603589.248) / (280620.964 / 614636.448)
=0.465675 / 0.456564
=1.02

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (233558.53 + 220523.866) / 573327.905) / (1 - (247275.776 + 215388.999) / 581369.711)
=0.207988 / 0.204181
=1.0186

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=614636.448 / 603589.248
=1.0183

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(21605.165 / (21605.165 + 215388.999)) / (24591.674 / (24591.674 + 220523.866))
=0.091163 / 0.100327
=0.9087

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(136704.818 / 614636.448) / (121576.665 / 603589.248)
=0.222416 / 0.201423
=1.1042

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((62045.008 + 207869.154) / 573327.905) / ((60718.895 + 205764.698) / 581369.711)
=0.470785 / 0.458372
=1.0271

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(2632.033 - 0 - 18181.846) / 573327.905
=-0.027122

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Daewon Pharmaceutical Co has a M-score of -2.79 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.79 mean?
Daewon Pharmaceutical Co (XKRX:003220) has a Beneish M-Score of -2.79 as of Aug. 15, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Daewon Pharmaceutical Co and its competitors. According to the industry distribution chart, Daewon Pharmaceutical Co ranks #234 out of 913 companies in the Drug Manufacturers industry, placing it in the top 25.6%.
Is Daewon Pharmaceutical Co's Beneish M-Score too high?
Daewon Pharmaceutical Co's current Beneish M-Score is -2.79. Based on the distribution chart, Daewon Pharmaceutical Co ranks #234 out of 913 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Daewon Pharmaceutical Co has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Daewon Pharmaceutical Co's Beneish M-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Daewon Pharmaceutical Co ranks #234 out of 913 companies for Beneish M-Score. This puts Daewon Pharmaceutical Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Daewon Pharmaceutical Co and its competitors. Daewon Pharmaceutical Co's current Beneish M-Score is -2.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daewon Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Daewon Pharmaceutical Co (XKRX:003220) is currently considered Significantly Undervalued. The stock's GF Value™ is ₩14,490.07, compared to a current price of ₩7,960.00 — trading 45.1% below its estimated fair value. The current Beneish M-Score is -2.79. Daewon Pharmaceutical Co's overall GF Score™ is 72/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Daewon Pharmaceutical Co (XKRX:003220), the current Beneish M-Score is -2.79 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Daewon Pharmaceutical Co (XKRX:003220) Overvalued in 2026?

Based on GuruFocus' analysis, Daewon Pharmaceutical Co stock appears to be undervalued. The current stock price of ₩7,960.00 is trading 45.1% below its estimated GF Value™ of ₩14,490.07. GuruFocus considers Daewon Pharmaceutical Co to be Significantly Undervalued.

Key valuation signals for XKRX:003220:

  • Beneish M-Score: -2.79
  • GF Value™: ₩14,490.07 vs. price of ₩7,960.00 (45.1% below fair value)
  • GF Score™: 72/100 with 9 warning signs

No single metric tells the full story. See the XKRX:003220 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Daewon Pharmaceutical Co Business Description

Address 229-3 Yongdap-dong, Seongdong-gu, Seoul, KOR, 133-850
Daewon Pharmaceutical Co Ltd is active in the healthcare sector in Korea. Its main business involves antipyretics, respiratory drugs, cardiovascular drugs, and neuromuscular drugs. It also produces a range of health foods such as multivitamins. The company operates on a global basis.
72GF Score

Get the complete analysis for XKRX:003220

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₩7,960.00
Price
₩14,490.07
GF Value